Alzheimer's Disease First Blood Test, Available in the United States

Alzheimer's disease is very abrupt and surprising when elders are not taken to their physicians for a regular check-up. This kind of scenario is often portrayed in the media to establish a sorrowful and impactful drama that will move the viewers' hearts. However, this can happen when symptoms like forgetfulness are usually common in elders. According to Mayo Clinic, a key component in diagnosing Alzheimer's disease is self-reporting about symptoms and information from a close family member or someone who can provide symptoms and impact the patient's daily activities.

ALSO READ: Researchers Reveal How a Keto Diet Could Help Reduce Alzheimer-Causing Fungi in the Gut

Since, traditionally, observation on the manifestation of the diseases is critical for the experts to determine whether a patient is positive for the diseases, it is difficult to bear for the family members if their loved one is diagnosed with Alzheimer's abruptly. With the advancement of technology, the first blood test that can help diagnose Alzheimer's diseases in patients is now available in the United States. However, some experts have several concerns about it. 

C2N Diagnostic's blood tests target elders aging 60 years and older who may have cognitive issues and are suspected of Alzheimer's disease. According to the Associated Press, the said blood test is not intended for general screening or for people who do not have the said disease symptoms. Costing $1250 with discounts based on the patient's income, the diagnostic test for Alzheimer's diseases will not be covered by insurance. Doctors are the only authorized ones who can order the test. 

READ ALSO: Is Hearing Loss Responsible for Millions of Dementia Cases Worldwide? Here's What Scientists Say

Experts Views

Associated Press also noted that the test could make it easier for the masses to know whether they are susceptible to the disease or already have the disease. Independent experts express their worries about the diagnostic test. As reported by the Associated Press, independent experts noted that information about the diagnostic test's accuracy is not yet published, alongside the fact that the United States Food and Drug Administration (FDA) is not yet approving the blood test. 

According to the United States National Institute on Aging's neuroscience chief, Eliezer Masliah, M.D. said that the US government funded some of the research leading to the tests. He added in the interview with Associated Press that he would be cautious about interpreting the thing regarding the promising claims of the company, C2N Diagnostics. He emphasized that the federal agency is encouraged and interested; however, they want to see results. 

Vice President of Medical and Scientific Relation from the Alzheimer's Association, Heather Synder, Ph.D., said in an interview with the Associated Press that the association would not endorse a test without the U.S FDA's approval. She also emphasized that the tests need to be studied in a larger and more diverse population. She also notes in the interview that it is still unclear how accurate the blood test results are. While waiting for more accurate results, it is blissful to know that diagnosis of the notorious diseases will greatly help experts find a way to lessen and even treat Alzheimer's disease.  

READ NEXT: Why Alzheimer's Disease Patients Travels Back in Time and Reminisce Their Past

Check out more news and information on Alzheimer's Disease on MD News Daily.

© MD News Daily.